2013
DOI: 10.1016/j.respe.2012.04.007
|View full text |Cite
|
Sign up to set email alerts
|

Les dépenses de soins remboursés durant la dernière année de vie, en 2008, en France

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 13 publications
0
5
0
Order By: Relevance
“…Our results show that acute hospital care was the main cost driver, representing 54% of total spending, whatever the main diagnosis class, and that spending of the last year of life markedly differed between diagnosis classes. There is a growing trend in end-of life expenditures per patient which represented 22,000 € (2015 current €)/patient in 2008 and 28 000 € in 2015 (5).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Our results show that acute hospital care was the main cost driver, representing 54% of total spending, whatever the main diagnosis class, and that spending of the last year of life markedly differed between diagnosis classes. There is a growing trend in end-of life expenditures per patient which represented 22,000 € (2015 current €)/patient in 2008 and 28 000 € in 2015 (5).…”
Section: Discussionmentioning
confidence: 99%
“…[4] In 2008, an estimate for France reported that end-of life care represented 10.5% of yearly health expenditures. [5] An international comparison in 2017 found that spending during the last 12 months of life ranged from 8.5% (USA) to 11.2% (Taiwan) of aggregate spending. [1] Authors also found that, although spending during the last 12 months of life was not wasteful, the money could be expended to provide better care.…”
Section: Introductionmentioning
confidence: 99%
“…The medical spending considered were those during the calendar year of death. In France, the average annual expenditure for cancer patients 1 year before death was estimated at €36,589 in 2008 [20]. Moreover, spending concentration around several expenditure items has also been studied.…”
Section: Introductionmentioning
confidence: 99%
“…Many of these patients benefit from high-level and costly treatments throughout their lives, particularly at the final stage of their illness. 2 , 3 Most of these treatments are prescribed as “home treatments” to keep the patients at home as long as possible. This strategy is in accordance with the desire expressed by most patients to spend the last part of their lives at home and is reinforced by political and economic strategies intended to develop ambulatory care and home treatments.…”
Section: Introductionmentioning
confidence: 99%
“…The risk of not respecting the wishes of the patient and of aggressive and futile therapy is considerable, and specific treatments, such as analgesia, sedation, or anxiolysis, are not necessarily well mastered in these palliative situations. 2 …”
Section: Introductionmentioning
confidence: 99%